cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Andress, Jason. Winterfeld, Steve. (2011). Cyber Warfare: Techniques, Tactics and Tools for Security Practitioners. Syngress. ISBN 1-59749-637-5 Bodmer, Kilger, Carpenter, & Jones (2012). Reverse Deception: Organized Cyber Threat Counter-Exploitation. New York: McGraw-Hill Osborne Media. ISBN 0-07-177249-9, "ISBN 978-0-07-177249-5" Brenner, S. (2009). Cyber Threats: The Emerging Fault Lines of the Nation State. Oxford University Press. ISBN 0-19-538501-2 Carr, Jeffrey. (2010). Inside Cyber Warfare: Mapping the Cyber Underworld. O'Reilly. ISBN 978-0-596-80215-8 Conti, Gregory. Raymond, David. (2017). On Cyber: Towards an Operational Art for Cyber Conflict. Kopidion Press. ISBN 978-0-692-91156-3 Cordesman, Anthony H.; Cordesman, Justin G. (2002). Cyber-threats, Information Warfare, and Critical Infrastructure Protection: Defending the U.S. Homeland. Greenwood Publishing Group. ISBN 978-0-275-97423-7. Costigan, Sean S.; Perry, Jake (2012). Cyberspaces and global affairs. Farnham, Surrey: Ashgate. ISBN 978-1-4094-2754-4. Fritsch, Lothar & Fischer-Hübner, Simone (2019). Implications of Privacy & Security Research for the Upcoming Battlefield of Things. Journal of Information Warfare, 17(4), 72–87. Gaycken, Sandro. (2012). Cyberwar – Das Wettrüsten hat längst begonnen. Goldmann/Randomhouse. ISBN 978-3-442-15710-5 Geers, Kenneth. (2011). Strategic Cyber Security. NATO Cyber Centre.
Thyroid hormone is required for the normal functioning of numerous tissues in the body. In healthy individuals, the thyroid gland predominantly secretes thyroxine (T4), which is converted into triiodothyronine (T3) in other organs by the selenium-dependent enzyme iodothyronine deiodinase. Triiodothyronine binds to the thyroid hormone receptor in the nucleus of cells, where it stimulates the turning on of particular genes and the production of specific proteins. Additionally, the hormone binds to integrin αvβ3 on the cell membrane, thereby stimulating the sodium–hydrogen antiporter and processes such as formation of blood vessels and cell growth. In blood, almost all thyroid hormone (99.97%) are bound to plasma proteins such as thyroxine-binding globulin; only the free unbound thyroid hormone is biologically active. Electrocardiograms are abnormal in both primary overt hypothyroidism and subclinical hypothyroidism. T3 and TSH are essential for the regulation of cardiac electrical activity. Prolonged ventricular repolarization and atrial fibrillation are often seen in hypothyroidism. The thyroid gland is the only source of thyroid hormone in the body; the process requires iodine and the amino acid tyrosine. The gland takes up iodine in the bloodstream and incorporates it into thyroglobulin molecules. The process is controlled by the thyroid-stimulating hormone (TSH, thyrotropin), which is secreted by the pituitary. Not enough iodine, or not enough TSH, can decrease thyroid hormone production.
== History == The FODMAP concept was first published in 2005. In this paper, it was proposed that a collective reduction in the dietary intake of all indigestible or slowly absorbed, short-chain carbohydrates would minimize stretching of the intestinal wall. This was proposed to reduce stimulation of the gut's nervous system and provide the best chance of reducing symptom generation in people with IBS (see below). At the time, there was no collective term for indigestible or slowly absorbed, short-chain carbohydrates, so the term FODMAP was created to improve understanding and facilitate communication of the concept. The low-FODMAP diet was originally developed by a research team at Monash University in Melbourne, Australia. The Monash team undertook the first research to investigate whether a low-FODMAP diet improved symptom control in patients with IBS and established the mechanism by which the diet exerted its effect. Monash University also established a rigorous food analysis program to measure the FODMAP content of a wide selection of Australian and international foods. The FODMAP composition data generated by Monash University updated previous data that was based on limited literature, with guesses (sometimes wrong) made where there was little information.
Sources: en.wikipedia.org
In ophthalmology, choroidal neovascularization is the formation of a microvasculature within the innermost layer of the choroid of the eye. Neovascularization in the eye can cause a type of glaucoma (neovascularization glaucoma) if the new blood vessels' bulk blocks the constant outflow of aqueous humour from inside the eye.
He starred in a 2003 series of Australian television commercials for Visa, titled Unexplained (about the raining of fish from the sky over Norfolk) and Big Cats (about the Beast of Bodmin Moor). In these commercials, Henriksen speaks as a Frank Black-type character about these phenomena as Mark Snow-inspired mysterious music plays in the background, as a link to Henriksen's TV series Millennium. Unexplained went on to a gold world medal at the 2004 New York Festivals. He made a cameo appearance in the 2009 horror comedy Jennifer's Body, and starred in the After Dark Horrorfest film Scream of the Banshee, released in 2011. He played Henry Gale in Leigh Scott's The Witches of Oz. In January 2015, he was signed for the lead in the indie thriller Monday at 11:01 am In 2016, he starred in the feature film Deserted, a psychological thriller. Henriksen played the role of Hopper. In 2018, Henriksen performed motion capture and vocal performance for the character of Carl Manfred in the video game Detroit: Become Human. The game's plot involves androids gaining sentience and free will, topics explored briefly with Henriksen's Bishop character in Aliens. In October 2018, Henriksen was signed for one of the two leads in Falling, the directorial debut of actor Viggo Mortensen, who also wrote, produced and co-starred.
Instant coffee (Two packets) Coffee creamer (One packet, four grams) Sugar (One packet, six grams) Candy-coated gum (Two pieces) Compressed fruitcake bar or Tropical Bar Toilet paper Cardboard matches (One book) Cigarettes (Four sticks; eliminated in 1975) Although compact, the LRP daily ration was 'energy depleted', supplying 5,000 kilojoules (1,200 kcal) less energy per day than the MCI.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.